SR-B1-targeted nanodelivery of anti-cancer agents: a promising new approach to treat triple-negative breast cancer

Patients with triple-negative breast cancer (TNBC) have a considerably less favorable prognosis than those with hormone-positive breast cancers. TNBC patients do not respond to current endocrine treatment and have a 5-year survival prognosis of <30%. The research presented here is intended to fil...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Rebecca, Sabnis, Nirupama, Sun, Xiangle, Ahluwalia, Ruhani, Lacko, Andras G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479299/
https://www.ncbi.nlm.nih.gov/pubmed/28670138
http://dx.doi.org/10.2147/BCTT.S131038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479299/
https://www.ncbi.nlm.nih.gov/pubmed/28670138
http://dx.doi.org/10.2147/BCTT.S131038

Ejemplares similares